# Marker Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Marker Therapeutics, Inc.). ## Overview Marker Therapeutics, Inc. is a clinical-stage cell therapy company developing multi-antigen targeted T-cell therapies, with a focus on its MAR-T platform and lead candidates such as MT-601 and MT-401. The company does not yet sell approved products and currently funds development through grants, equity financing, and collaborations with research and manufacturing partners. ## Products & services • MT-601 MAR-T cell therapy candidate • MT-401 off-the-shelf (OTS) AML program • Clinical-stage cell therapy pipeline • Process development and cGMP manufacturing collaboration • Grant-funded translational and clinical research - **Cell therapy product candidates** (0%) — Clinical-stage MAR-T and OTS cell therapies being developed for AML, MDS, and other cancers. - **Research grants** (100%) — Government and institutional grants that fund qualifying R&D and clinical trial activity. - **Manufacturing and process development** (0%) — Technology transfer, process development, and outsourced cGMP manufacturing support for pipeline programs. - MT-601 MAR-T cell product candidate - MT-401 off-the-shelf (OTS) AML program - Clinical-stage pipeline in hematologic and solid tumors - cGMP manufacturing via Cellipont and other CDMOs - Grant-supported clinical development programs ## Customers Marker Therapeutics' direct economic counterparties are not commercial customers but grant agencies, clinical investigators, and manufacturing partners that support development of its product candidates. The eventual end users are patients with difficult-to-treat cancers such as AML and MDS, while the near-term buyers of services are public funding bodies and CDMOs that enable clinical execution. - **Government grant agencies** (primary) — CPRIT, FDA, and NIH fund specific development programs and reimburse qualifying research costs. - **Clinical trial sites and investigators** (primary) — Academic and clinical centers run studies for MT-401 and MT-601 and generate the data needed for approval. - **CDMO and manufacturing partners** (primary) — Cellipont and other third parties provide technology transfer, process development, and cGMP manufacturing. - **Future oncology treatment centers** (emerging) — If approved, hospitals and cancer centers would purchase and administer the therapies. - Government grant agencies funding AML and oncology research - Clinical investigators and trial sites running MAR-T studies - CDMOs providing technology transfer and cGMP manufacturing - Future hospitals and oncology centers if products are approved - Patients with AML, MDS, and metastatic pancreatic cancer ## Geography Marker Therapeutics is headquartered in the United States and its development, manufacturing, and regulatory activities are centered there. The company previously operated cGMP facilities in Houston, Texas, and now relies on U.S.-based third-party manufacturing and U.S. clinical/regulatory infrastructure, making it highly exposed to FDA, NIH, and U.S. capital market conditions. - United States is the core operating and regulatory market - Houston, Texas has been the main manufacturing base - Clinical and cGMP work is now outsourced to U.S. partners - FDA, NIH, and SEC actions directly affect development timing - Capital access depends on U.S. public markets and investor appetite ## Strategy The company is focused on advancing MT-601 and MT-401 through clinical development while preserving cash through outsourced manufacturing and grant funding. Near-term priorities are technology transfer, patient enrollment, and generating early safety/efficacy data that can support additional financing, partnerships, and eventual regulatory filings. - **Clinical advancement of MT-601** (short-term) — The lead program needs manufacturing scale-up and clinical data to validate the MAR-T platform. - **Progress MT-401 OTS development** (short-term) — The off-the-shelf AML program could broaden the platform and address rapidly progressing diseases. - **Preserve liquidity and extend runway** (short-term) — The company has no commercial revenue and must fund operations through external capital and grants. - **Outsource manufacturing and scale process quality** (medium-term) — Third-party cGMP manufacturing reduces capital intensity and supports commercial scalability if approved. - Advance MT-601 through APOLLO study manufacturing and clinical work - Develop MT-401 OTS program for AML and MDS indications - Use third-party CDMOs to reduce fixed manufacturing overhead - Pursue additional grants, equity, and selective partnerships - Build data package for future regulatory and commercialization steps ## Risks Marker Therapeutics faces classic clinical-stage biotech risks: program failure, regulatory delay, and dependence on external capital before any product revenue exists. Its business is also exposed to government funding disruptions, FDA review delays, and the risk that outsourced manufacturing or clinical execution does not scale as planned. - **Clinical development failure** [critical] — The company has no approved products, so negative trial results would impair the core asset base. - **Financing and liquidity shortfall** [critical] — Operations are funded through equity, debt, and grants, with no recurring product revenue. - **Regulatory delay or disruption** [high] — FDA review timing and NIH/FDA grant administration can be slowed by staffing, budget, or shutdown issues. - **Manufacturing execution risk** [high] — The company relies on third parties for cGMP manufacturing and technology transfer. - **Dilution from equity financing** [high] — ATM and other equity raises can materially dilute existing shareholders. - No commercial revenue; survival depends on financing and grants - Clinical trial failure could eliminate value of lead programs - FDA or NIH delays can slow approvals and grant-funded work - Outsourced manufacturing adds execution and quality risk - Government shutdowns can disrupt regulatory and capital access - Going-concern risk remains due to limited cash runway ## Accounting Revenue is primarily grant income, recognized only when qualifying costs are incurred and the company is entitled to reimbursement under the grant terms. That makes quarterly revenue highly dependent on R&D spending patterns, while deferred revenue and restricted cash can arise when grant funds are received before qualifying costs are incurred. - **Grant income recognition** — Quarterly revenue volatility and deferred revenue balances - **Restricted cash and deferred revenue** — Liquidity presentation and liability recognition - **Going concern assessment** — Financial statement basis and investor risk perception - **Stock-based compensation and ATM financing** — Net loss, share count, and per-share metrics - Grant income recognition follows qualifying cost incurrence - Quarterly revenue can move with clinical spending timing - Restricted cash and deferred revenue may reflect unspent grants - Going-concern disclosure signals material liquidity uncertainty - Stock-based compensation and equity issuance affect reported losses --- *Last updated: 2026-04-28T20:26:21.626744+00:00*